NASA Logo

NTRS

NTRS - NASA Technical Reports Server

Back to Results
Astropharmacy: in-Space Pharmaceutical Manufacturing for Deep Space MissionsDuring long-duration spaceflight beyond Low Earth Orbit (LEO), astronauts will be exposed to increased health risks that will require medical countermeasures. Biologics (e.g., peptide-based drugs) are particularly well-suited to treat many of the spaceflight-induced medical conditions. However, supplying these pharmaceuticals will be challenging due to reduced drug stability in space, limited shelf-life (6 months for biologics) even when refrigerated, and mass/volume constraints. To address this challenge, we are developing a platform for on-demand production of small doses of pharmaceuticals in deep space. This platform uses engineered Bacillus subtilis bacteria, which can be transported and stored in space as durable dried spores. When an astronaut gets sick, these spores will be activated inside a custom microfluidic hardware system to initiate production of the required drug. Seven small peptide drugs with relevant indications (e.g., bone loss and post-radiation exposure treatments) have been successfully expressed in B. subtilis to date. Several prototypes have been developed to translate laboratory culture and purification procedures into a hardware system to enable start-to-finish production in space, with minimal crew involvement. For each prototype, we are deriving the Figures of Merit (mass, power, volume, crew time), which are being compared to traditional laboratory protocols. The implementation of the “Astropharmacy” during long-duration missions beyond LEO will be discussed using a test scenario where an astronaut develops neutropenia (low white blood cells) following a solar particle event. Overall, the ability to produce small quantities of pharmaceuticals on-site, on-demand, with minimal power, mass and crew time requirements will address a major barrier to keeping astronauts healthy during long-duration spaceflight beyond LEO. On Earth, this platform could be beneficial in field situations with similar logistical constraints, such as in war zones, extended submarine deployments, or remote communities. This approach could enable personalized treatments in space and on Earth and make orphan drugs more affordable, while making the development of new drugs more rapid.
Document ID
20250007096
Acquisition Source
Ames Research Center
Document Type
Abstract
Authors
Alina Kunitskaya
(NASA Postdoctoral Program Oak Ridge, United States)
Jessica Snyder
(Blue Marble Space Institute of Science Seattle, Washington, United States)
Rebecca Blum
(Brown University Providence, Rhode Island, United States)
Dorra Omrani
(Brown University Providence, Rhode Island, United States)
David Loftus
(Ames Research Center Mountain View, United States)
Lynn Rothschild
(Ames Research Center Mountain View, United States)
Date Acquired
July 16, 2025
Subject Category
Aerospace Medicine
Meeting Information
Meeting: 76th International Astronautical Congress (IAC)
Location: Sydney
Country: AU
Start Date: September 29, 2025
End Date: October 3, 2025
Sponsors: The International Astronautical Federation
Funding Number(s)
WBS: 393748.20.23.01.21
Distribution Limits
Public
Copyright
Portions of document may include copyright protected material.

Available Downloads

There are no available downloads for this record.
No Preview Available